Sandoz ACA Violation Unlikely In Amgen Suit, Judge Says

Law360, San Francisco (March 13, 2015, 5:24 PM ET) -- A California federal judge said Friday he's unlikely to rule that Sandoz Inc. flouted the Affordable Care Act by failing to notify Amgen Inc. of its biosimilar version of a blockbuster drug for cancer patients, putting Amgen's bid for an injunction in doubt.



U.S. District Judge Richard Seeborg, who is presiding over the case, said he doesn't agree with Amgen's argument that a provision in the ACA which says a biosimilar sponsor “shall provide” rivals with notice of its application for approval means the notice is...

To view the full article, register now.